News

21Mar

Biocartis Announces Nine Idylla™ Studies Published at AMP 2022 Annual Meeting

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracy, ease-of-use and rapid time-to-results.

biocartis, EGFR, gene fusion, GeneFusion Assay, idylla, Immunexpress, molecular testing, next generation sequencing, SeptiCyte RAPID

03Feb

Molecular

Invivoscribe’s EHA Symposiums Now Available on Demand

Products are for professional/laboratory use only.

The Invivoscribe symposiums presented during the 25^th European Hematology Association Virtual Congress are now available to watch on demand.

eha symposium, invivoscribe, MRD, MRD monitoring, next generation analysis, next generation sequencing, NGS

03Feb

Molecular

Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Products are for professional/laboratory use only.

Press Release: Mechelen, Belgium, 27 June 2018

biocartis, braf, cancer, EGFR, idylla, KRAS, next generation sequencing, NGS, nras, tumour

03Feb

Molecular

Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Products are for professional/laboratory use only.

A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).

biocartis, EGFR, idylla, lung cancer, next generation sequencing, NGS